DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/AGM/EGM26.10.2020 / 10:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG Berlin, October 26, 2020 – The Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) notifies that according to […]
Category: Press Releases
19. October 2020
Epigenomics AG hosts conference call on preliminary CMS reimbursement decision
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous19.10.2020 / 08:30 The issuer is solely responsible for the content of this announcement. Epigenomics AG hosts conference call on preliminary CMS reimbursement decision Berlin (Germany) and San Diego, CA (USA), October 19, 2020 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) is appalled and vehemently […]
31. August 2020
Epigenomics AG: CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible
DGAP-News: Epigenomics AG / Key word(s): Miscellaneous31.08.2020 / 07:34 The issuer is solely responsible for the content of this announcement. CMS Still Actively Working on Proposed Decision Memo with Goal to Publish As Soon As Possible Berlin (Germany) and San Diego, CA (USA), August 31, 2020 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; […]
13. August 2020
Epigenomics AG presents operational highlights and reports financial results for first six months of 2020
DGAP-News: Epigenomics AG / Key word(s): Half Year Results/Quarter Results13.08.2020 / 08:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG presents operational highlights and reports financial results for first six months of 2020 Berlin (Germany) and San Diego, CA (U.S.A.), August 13, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, […]
10. August 2020
New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening
DGAP-News: Epigenomics AG / Key word(s): Study results/Study10.08.2020 / 08:00 The issuer is solely responsible for the content of this announcement. New study published in the Journal of the National Cancer Institute concludes that Epi proColon(R) is the test of choice for the millions of individuals not willing to participate in FIT or colonoscopy screening […]
16. June 2020
Epigenomics AG to Participate in Raymond James Human Health Innovations Conference
DGAP-News: Epigenomics AG / Key word(s): Conference/Miscellaneous16.06.2020 / 10:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG to Participate in Raymond James Human Health Innovations Conference Berlin (Germany) and San Diego, CA (U.S.A.), June 16, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management […]